John Chung, MD
MOHS-Micrographic Surgery · Dalton, GANPI 1710943709
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,234 of the $6,484 with a category attached, or 80.7%. It is spread thinly across 31 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,409 and has fallen 78.9% since, to $718 in 2025.
Across 182 payments — averaging $35.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$1K
- Merz North America, Inc.$1K
- AbbVie$1K
- Novartis$481
- Lilly USA, LLC$403
- Regeneron Healthcare Solutions, Inc.$344
- plus $2K from 25 others
What the payments were for
- Consulting fees$1,20019%
- Food & beverage$5,23481%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 2 | $1,262 |
| Merz North America, Inc. | 9 | $1,075 |
| AbbVie(2 entities) | 37 | $1,073 |
| Novartis | 11 | $481 |
| Lilly USA, LLC | 16 | $403 |
| Regeneron Healthcare Solutions, Inc. | 15 | $344 |
| Mimedx Group, Inc. | 6 | $274 |
| Sun Pharmaceutical Industries Inc. | 7 | $208 |
| Johnson & Johnson | 12 | $197 |
| Pfizer | 12 | $177 |
| Strata Skin Sciences, Inc. | 11 | $126 |
| Sanofi | 3 | $117 |
| UCB, Inc. | 4 | $104 |
| LEO Pharma Inc. | 6 | $102 |
| Galderma Laboratories, L.p. | 6 | $101 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $74 |
| Genentech USA, Inc. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 1 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Mayne Pharma Commercial LLC | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Aclaris Therapeutics, Inc. | 2 | $24 |
| Organogenesis Inc. | 1 | $24 |
| EPI Health, LLC | 1 | $17 |
| Dermavant Sciences, Inc. | 1 | $17 |
| Medline Industries LP | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Amgen | 1 | $15 |
| Medtronic | 1 | $15 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
| Glenmark Therapeutics Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,484 in reported general payments places this provider in the 65th percentile of 40 mohs-micrographic surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 71 | $534,516 |
| Humira(Cf) PenAdalimumab | 29 | $313,139 |
| Skyrizi PenRisankizumab-Rzaa | 13 | $263,615 |
| Dupixent PenDupilumab | 44 | $164,974 |
| Dupixent SyringeDupilumab | 29 | $114,265 |
| OtezlaApremilast | 17 | $87,741 |
| Cephalexin | 2,390 | $17,136 |
| Doxycycline Monohydrate | 743 | $8,593 |
| Doxycycline Hyclate | 625 | $6,185 |
| Clobetasol Propionate | 119 | $6,063 |
| Cyclosporine ModifiedCyclosporine, Modified | 23 | $3,748 |
| Tramadol Hcl | 2,062 | $2,835 |
| Ketoconazole | 163 | $2,822 |
| Triamcinolone Acetonide | 171 | $1,983 |
| Metronidazole | 23 | $1,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $15 | $87,74117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 40 mohs-micrographic surgery providers in Georgia.
Other mohs-micrographic surgery in Dalton
- Wallace NozileStockbridge$213K
- Brandon BurrowayDuluth$30K
- John KayalMarietta$27K
- David HarveyNewnan$17K
- David OlanskyAtlanta$13K
- David KentMacon$11K
- Diamondis PapadopoulosAtlanta$9K
- Sidney SmithSavannah$9K
- Steven KentMacon$8K
- Danielle LazzaraMilton$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.